Biocartis, BD, and Abbott, are expected to Dominate the Global Cancer Spit Test Device Market in 2020

Global Cancer Spit Test Device Market is expected to grow with the CAGR of 9.7% in the forecast period of 2021 to 2028. The years considered for study are as mentioned below.

Access Full Report @ https://www.databridgemarketresearch.com/reports/global-cancer-spit-test-device-market

Global cancer spit test device market is highly consolidated and includes specific number of key players. The market has witnessed increased strategic developments owing to favorable market scenario.    

Major players operating in the global cancer spit test device market are introducing a wide range of products and adopting strategic initiatives, such as acquisitions and agreements into the market. This helps the companies to maximize their sales with enhanced product portfolio.

For instance,

  • In April 2021, Biocartis and SkylineDx announced new partnership agreement, which targets the development of SkylineDx’ novel proprietary test, the Merlin Assay, on Biocartis’ rapid and easy-to-use molecular diagnostics platform Idylla. This assay is aimed at predicting a patient’s risk of nodal metastasis in melanoma. This partnership enhanced the credibility of the company in the market and aided in revenue generation.

Biocartis is the dominating player in global cancer spit test device market. Other key players operating in the market include DNA Genotek, Salimetrics, LLC, PeriRx, Color Health, Inc., SARSTEDT AG. Co. KG,  Miraclean Technology Co., Ltd.,  Agilent Technologies, Inc., Illumina, Inc., QIAGEN, Thermo Fisher Scientific Inc., Abbott, BD, Biocartis, bioMérieux SA, Siemens Healthcare GmbH, F. Hoffmann-La Roche Ltd,  Oasis Diagnostics Corporation, and Canvax (a subsidiary of dobuss) among others.

Cancer Spit Test Device Market Biocartis

Biocartis was established in 2007 and is headquartered in Mechelen, Belgium. It is an innovative molecular diagnostics company and is committed to revolutionize molecular testing with its unique proprietary IdyllaTM platform. The company also provides various product categories including Infectious disease, oncology, and pharma, in which oncology is the market focused category.

For instance,

  • In November 2018, Biocartis announced agreement with AstraZeneca to obtain faster lung cancer molecular diagnostic biomarker results in Europe. This agreement has increased the company's revenue in the market and strengthened the company's footprints in in the region.

The company has wide presence in Americas, Europe, Middle East and Africa, and Asia-Pacific. It has two subsidiaries companies, Biocartis SA (Switzerland) and MyCartis NV (Belgium).

BD

BD was incorporated in 1897 and is headquartered in New Jersey, the U.S. The company focuses on instruments used for diagnostic infectious disease. It offers a variety of products such as direct testing products, environmental systems, and prepared media products among others. It has various business segments including medical, life science and interventional, in which interventional is the market focused segment.  The company also provides various product categories including anesthesia delivery, biosciences, bio surgery, cervical cancer screening, diabetes care, drug delivery systems, gastrointestinal care, hazardous drug safety, hernia repair and fixation, home care, infection prevention, infusion therapy, interventional specialties, lab automation, women's health and cancer, medication and supply management, microbiology solutions, oncology, others, in which women’s health and cancer is the market focused category.. The company is engaged in several strategic initiatives to expand its market.

For instance,

  • In February 2014, BD announced that it had received CE mark approval forits product BD Onclarity HPV Assay on the new BD Viper LT System. After receiving approval, the company commercialized its product in the European region.

The company has wide presence across Americas, Europe, Middle East and Africa, and Asia-Pacific. It has various subsidiary companies including Accuri Cytometers, Inc.(Delaware), Accuri Cytometers (Europe), Ltd. (U.K.), Atto Bioscience, Inc. (Delaware), B-D (Cambridge U.K.) Ltd. (U.K.) among others.

Abbott

Abbott was founded in 1888 and is headquartered in Illinois, the U.S. The company focuses on manufacturing products in diagnostics, medical devices, nutrition, and branded generic pharmaceuticals that help people to live healthier lives, full of unlimited possibilities. The company operates in various business segments including established pharmaceutical products, nutritional products, diagnostic products, and medical devices in which diagnostic products is the market focused segment. The company also provides various product categories including consumers, healthcare professionals, and others, in which healthcare professionals is the market focused category.

The company has wide presence across Americas, Europe, Asia-Pacific, Oceania, and the Middle East and Africa. It has various subsidiary companies including Abbott Cardiovascular Systems Inc. (U.S.), Abbott Nutrition Manufacturing Inc. (U.S.), Abbott Laboratories Pacific Ltd. (U.S.), Abbott Resources Inc. (U.S.) and PDD II, LLC (U.S.) among others. The company is engaged in several strategic initiatives to expand its market.

For instance,

  • In December 2020, Abbott participated at the 39th Annual J. P. Morgan Healthcare Conference. This has helped the company showcase its best product, which will help the company grow in the coming years.